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Abstract
Prior behavioral studies in our laboratory revealed that overexpression of the stress
peptide, corticotrophin-releasing factor (CRF), in the mesocorticolimbic reward pathway
enhanced the reinforcing effects of nicotine. The latter effect was greater in female versus male
rats, suggesting that females are uniquely susceptible to the effects of stress on nicotine
reinforcement. The goal of this dissertation was to examine the neurochemical mechanisms by
which overexpression of CRF in the nucleus accumbens (NAc), a terminal region of the
mesocorticolimbic pathway, modulates the behavioral effects of nicotine. Specifically, we
examined whether nicotine-induced dopamine levels are altered by CRF overexpression via
excitatory (glutamate) and/or inhibitory (γ-aminobutyric acid; GABA) amino acid control of
dopamine release in the NAc of female versus male rats. The animals first received intra-NAc
infusion of a viral vector (AAV2/5-CRF) to overexpress CRF mRNA in one hemisphere. In the
contralateral NAc, a control viral vector (AAV2/5-GFP) was infused. Three weeks later, the rats
were implanted with dialysis probes in the NAc of each hemisphere. The following day,
dialysate samples were collected during baseline and then following administration of two doses
of nicotine (0.3 and 0.6 mg/kg/expressed as base). Dopamine, GABA, and glutamate levels were
assessed using liquid chromatography-mass spectrometry procedures. The results revealed that
during baseline, there were no sex differences in any of our neurochemical measures following
intra-NAc infusion of the control virus. Our statistical analysis revealed that only glutamate
levels were significantly altered by CRF overexpression in the NAc. Specifically, in males,
overexpression of CRF produced an increase in NAc glutamate levels during baseline and
following nicotine administration. However, in females, overexpression of CRF produced a
decrease in NAc glutamate levels during baseline and following nicotine administration. These
data suggest that stress systems promote excitatory glutamatergic regulation of the NAc in a sex-

dependent manner. Future studies are needed to examine the role of different glutamate receptors
in the NAc in modulating the behavioral effects of nicotine in female versus male rats.
Keywords: tobacco use, sex differences, microdialysis, dopamine, amino acids, CRF
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Chapter 1: Introduction
1.1 Tobacco use is a public health burden
High rates of tobacco use are a major economic and health concern. According to the Center
for Disease Control (CDC) and the World Health Organization (WHO), tobacco use is the leading
cause of preventable death and disease in the United States. With approximately 1.1 billion
smokers worldwide, the WHO has predicted that by 2030, tobacco use will cause an estimated 9
million deaths per year (WHO, 2011). Approximately 16 million people in the United States live
with a disease that is caused by smoking, such as chronic obstructive pulmonary disease,
emphysema, bronchitis, and various types of cancer (CDC, 2016). Xu et al (2015) found the annual
healthcare costs associated with tobacco smoking are more than $170 billion dollars, with public
healthcare such as Medicare and Medicaid accounting for more than 60% of those expenditures.
Women appear to be more susceptible to use tobacco products despite the known health
consequences. Although smoking rates are similar in men and women, females are less likely to
stop smoking and are more susceptible to the negative health consequences associated with longterm smoking as compared to men (Lombardi et al., 2011; Surgeon General, 2014). Women report
more often than men that they smoke in response to negative affective states (Perkins et al., 1999,
2012, and 2013; Stanton, 1995). Women also display stronger anxiety, depression, and intense
craving during smoking abstinence as compared to men (Leventhal et al., 2007; Panagiotakopoulos
& Neigh, 2014; Pang et al., 2018; Schnoll et al., 2007). Women with a prior history of an anxiety
disorder are also more likely to smoke and show higher relapse rates when compared to men
(Brook et al., 2012). Comparatively, there is a stronger co-morbid association between stress
disorders and smoking in women relative to men (Mykletun et al., 2008). Women with posttraumatic stress disorder report higher ratings of negative affect during abstinence (Dedert et al.,
2012) and display greater expectancies that smoking will relieve the negative affective states
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(Langdon and Leventhal, 2014). In general, women exhibit lower smoking cessation rates because
of a more severe withdrawal syndrome and, in part, the lack of efficacy and benefit of nicotine
replacement therapy as compared to men (Cepeda-Benito et al., 2004; Perkins 2001; Perkins and
Scott, 2008; Piper et al., 2010).
Although there are over 4,800 chemicals in tobacco products, nicotine is the major habitforming compound in tobacco products (Balfour, 2004). Nicotine is a mild stimulant and when
consumed, induces a feeling of euphoria, alertness, relaxation, and motor activation (Heishman et
al., 2010; Hukkanen et al., 2005; Le Foll and Goldberg, 2009). Indeed, nicotine is readily selfadministered by humans, dogs, rodents, and primates (Caille, 2012; Corrigall, 1999; Harvey et al.,
2004; Katner et al., 2004; Risner et al., 1983). The recent rise in electronic nicotine delivery
systems (i.e., ENDS) speaks to the strong motivational effects of nicotine (Drope et al., 2017;
Yoong et al., 2019). Following cessation from chronic nicotine use, a withdrawal syndrome
emerges that involves physical, affective, and cognitive aversive symptomatology. Importantly, it
is the avoidance of these negative symptoms that promotes the continued use of nicotine products
(O’Dell et al., 2014). Thus, the motivational effects of nicotine are modulated by its acute
pleasurable effects and avoiding the negative aversive states that emerge during withdrawal from
chronic nicotine use (Balfour, 2004; Mansvelder et al., 2002; Sohn et al., 2003).
1.2 Mesocorticolimbic pathway
The mesocorticolimbic pathway originates in the ventral tegmental area (VTA) and terminates
in several forebrain structures including the nucleus accumbens (NAc) and the prefrontal cortex
(PFC) (Aston-Jones and Harris, 2004; Carelli and Wightman, 2004; Koob, 1996). This pathway
has been has been studied extensively with regard to modulating the rewarding effects of abused
drugs such as nicotine, ethanol, cocaine, and morphine (Corrigall, 1999; DiChiara et al., 1988;
Schuette et al., 2013). Lesions of the dopaminergic fibers in the NAc or administration of dopamine
2

antagonists into the NAc abolish the psychostimulant and rewarding effects of drugs (Bari and
Pierce 2005; Kelly and Iversen, 1976; Roberts and Koob 1982). In addition, several behavioral
animal models of drug addiction such as sensitization, conditioned place preference, and
intravenous self-administration (IVSA) are associated with increased dopaminergic activity of the
NAc (Beckmann et al., 2011; Cadoni and Di Chiara, 2000; Torres et al., 2015). Together, these
studies suggest that the NAc is a critical structure that modulates the addictive properties of drugs
of abuse.
Much work has established that the behavioral effects of nicotine are due to activation of
nicotinic acetylcholine receptors (nAChRs) in the brain, particularly in the mesocorticolimbic
pathway. nAChRs consist of pentameric transmembrane proteins of homomeric or heteromeric α
or β receptor subunit complexes. Nicotine binds to nAChR subunits, resulting in channel activation
and/or desensitization. There are different nAChRs expressed on the γ-aminobutyric acid (GABA)
and glutamate inputs that regulate dopamine release in the NAc (Johnson et al., 1992; Kalivas et
al., 1989; Kalivas et al., 1993; Mansvelder et al., 2003; Mansvelder & McGehee, 2002; Xu et al.,
2006). Dopamine cell bodies in the VTA express α2-10 and β2-4 nAChRs subunits that project to
the NAc (Mansvelder et al., 2003). In addition, within the VTA, GABAergic interneurons express
α4β2 nAChRs and PFC glutamate terminals express α7 nAChRs. Following administration of
nicotine, α4β2 sites on intra-VTA GABAergic interneurons are activated but then quickly
desensitize (Mansvelder et al., 2002). As a result, VTA dopamine neurons receive less GABAergic
inhibition. This effect of nicotine produces a reduction in inhibition that results in enhanced
activation of dopamine neurons. Nicotine also binds and sensitizes α7 nAChRs on PFC glutamate
terminals, causing a larger release of glutamate and a shift towards enhancement of VTA
dopaminergic neurons. (Wooltorton et al., 2003). As a result, nicotine produces a shift from tonic
inhibition towards excitation of VTA dopamine neurons that results in enhanced dopamine
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transmission in the NAc. Overall, desensitization of the α4β2 sites on VTA GABA neurons leads
to disinhibition of dopamine neurons thereby facilitating a more sustained increase in the release
of dopamine in the NAc following nicotine administration.
1.3 NAc cytoarchitecture
The NAc is a heterogeneous structure that integrates information from limbic and cortical
structures such as the frontal cortex, basolateral amygdala, hippocampus, and bed nucleus of stria
terminalis (Xu et al., 2020). The NAc is composed of two distinct subdivisions that differ in
projection targets, neurochemical profile, and cytoarchitecture (Wright and Groenewegen 1996).
The NAc core is an important in fine tuning and guiding motor behavior (Everitt et al., 2008),
whereas the NAc shell is important in the processing of emotional information related to
environmental stimuli and motivation (Kelley, 2004; Park et al., 2019). The shell of the NAc is
composed of GABAergic medium spiny neurons (>90%) that project back to the VTA, PFC, and
the caudate putamen (Meredith et al, 2008). It also has local populations of cholinergic and
GABAergic interneurons (<10%) (Castro and Bruchas 2019; Meredith 1999). There has been
evidence that these local population interneurons can be categorized into three populations; 1)
parvalbumin-positive neurons, 2) somatostatin-positive neurons, and 3) acetylcholine-releasing
neurons (Kawaguchi, 1993; Tepper et al., 2010). There is also evidence that suggests the
somatostatin-positive neurons are expressed most densely in the NAc shell (Ribeiro et al., 2018).
Interestingly, while there is a decrease in the number of parvalbumin-positive neurons, there is a
concomitant increase of somatostatin-positive neurons and acetylcholine-releasing neurons in the
NAc shell (Castro and Bruchas 2019). This suggests that GABAergic and cholinergic interneurons
are in greater number and exert greater action in the NAc shell than in the NAc core.
1.4 Stress
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The hypothalamic-pituitary-adrenal (HPA) axis modulates the stress response to maintain or
return to a homeostatic equilibrium in the body. The stress response begins with the activation of
the paraventricular nucleus of the anterior hypothalamus, where parvocellular cells synthesize and
release the stress peptide, corticotrophin-releasing factor (CRF), into the median eminence. CRF
then travels through the portal system and binds to CRF receptors located on the anterior pituitary
gland, causing the release of adrenocorticotropin hormone (ACTH) into the hypophysial portal
circulation. Finally, ACTH binds to glucocorticoids receptors on the fasciculate cells of the adrenal
cortex, stimulating the release of the stress hormone, cortisol in humans or corticosterone in
rodents, and initiating the stress response (Vale et al., 1982; Thiel et al., 1999).
CRF has been implicated as a neuromodulator in extrahypothalamic brain regions that govern
limbic and cognitive functions (Smith et al., 2006; Swanson et al., 1983). CRF binds to and exerts
its actions through two distinct G-protein coupled receptors, CRF1 and CRF2. One of the roles of
the CRF1 receptor is activating the HPA axis, resulting in changes of behavioral, affective, and
cognitive function. Genetic knockout of CRF1 receptors in rodents results in the attenuation of
anxiety-like behaviors such as freezing, avoidance, and startle responses (Heinrichs et al., 1997;
Hikichi et al., 2000; Schulz et al., 1996; Smith et al., 1998). The distribution of CRF1 receptors in
the brain reflects its many roles as studies have found its expression in the cortices, hypothalamus,
and throughout the mesolimbic pathway (Albrechet-Souza et al., 2015; Van Pett et al., 2000).
Although there is conflicting literature with the specific role of CRF2 receptors in stress (Ho et al.,
2001; Takahashi et al., 2001), it is generally thought that CRF2 receptors reduce anxiety-like
behavior (Bale et al., 2004). In contrast to CRF1, CRF2 receptors expression is restricted to
discrete brain regions including the periaqueductal gray and lateral septum (Hauger et al., 2006;
Sanders et al., 2016). Although there is expression of CRF2 receptors in the NAc, their distribution
is sparse in comparison to CRF1 receptors, suggesting the actions of CRF1 largely control
5

neurotransmission in the mesocorticolimbic pathway (Hauger et al., 2006; Lemos et al., 2012;
2019).
In addition to initiating the stress response, CRF plays a neuromodulatory role in the NAc.
There is a population of CRF mRNA positive neurons in the NAc, suggesting that the possible
presence of local stress systems that modulate dopamine release and dopamine-dependent
behaviors (Chen et al, 2012; Lemos et al., 2019; Merchenthaler et al., 1984; Peng et al., 2017).
Stress systems in the NAc shell have been implicated in mediating the transition of causal drug
use into dependence via potentiation of the rewarding effects of drugs and the emergence of a
negative affective and emotional withdrawal syndrome (Koob 2010; Koob et al., 1996; Roberto et
al., 2017). Both acute and chronic administration of drugs of abuse activates the HPA axis
(Goeders 1997; Piazza et al., 1993; Piazza et al., 1997). Pre-clinical research has shown chronic
nicotine use recruits stress systems in extrahypothalamic areas that promote nicotine use in rodent
models (Koob and Kreek, 2007; Semba et al., 2004). Brain slices from male mice have shown that
CRF increases dopamine release in the NAc (Lemos et al., 2012) and administration of yohimbine,
a pharmacological stressor that increases CRF, reinstates extinguished nicotine IVSA in both
female and male rats (Feltenstein et al., 2012). Overall, these data show that CRF systems in the
NAc potentiate the behavioral effects of nicotine, as described below.

1.5 Dissertation Studies
Prior to my Dissertation studies, I co-authored a meta-analysis showing that intact females
display higher levels of nicotine IVSA than males (Flores et al., 2019). To better understand the
mechanisms of sex differences in the behavioral effects of nicotine, my subsequent work compared
nicotine self-administration following viral overexpression of CRF in the NAc shell. The results
6

revealed that CRF overexpression in the NAc shell increased the reinforcing effects of nicotine in
a sex- and ovarian hormone dependent manner (Uribe et al., 2020). Specifically, overexpression
of CRF in the NAc selectively increased the reinforcing effects of nicotine in intact female versus
male rats. The latter effect was absent in ovariectomized (OVX) females, suggesting that the
potentiating effects of CRF overexpression in the NAc are ovarian-hormone dependent. Real time
quantitative polymerase chain reaction (rt-qPCR) methods also revealed that CRF overexpression
enhanced mRNA expression of CRF1 and CRF2 receptors to a greater extent in intact female
versus male rats. Overexpression of CRF also produced a larger increase in β-arrestin2 (Arrb2) in
male versus intact and OVX female rats. This is important, as Arrb2 is a protein that internalizes
CRF receptors. These data suggest that CRF systems in the NAc play a role in modulating sex
differences in the behavioral effects of nicotine. To verify that the effects of the viral vector were
localized in the NAc (and not due to the vector being retrograde transported to the VTA), we
collected coronal slices of the NAc shell and VTA. Subsequent immunohistochemistry analysis
revealed co-localization of viral replication of green fluorescence protein (GFP) and the neuronal
markers, neuronal nuclei (NeuN) and 4′,6-diamidino-2-phenylindole (DAPI), in the shell of the
NAc. Viral infusions produced a stable and localized overexpression of GFP in the NAc shell and
analysis of AAV2/5-mediated transduction efficiency in neurons revealed that a majority of GFPpositive cells were DAPI- and NeuN-positive (90%), suggesting that the cells that were transduced
by the virus were neurons. Importantly, we did not observe any fluorescence in the VTA,
suggesting that overexpression of CRF was isolated to the NAc and not back transported to the
cell body region of the VTA. This prior work was important for validating our viral overexpression
procedures. However, there were still remaining questions regarding the manner in which stress
systems modulate the neurochemical environment of the NAc, particularly following nicotine
administration in female and male rats.
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To address this question, my dissertation work assessed whether overexpression of CRF in the
NAc alters inhibitory (GABA) and excitatory (glutamate) amino acid regulation of dopamine
release in female and male rats during baseline (Aim 1) and following nicotine administration
(Aim 2). We examined dopamine, glutamate, and GABA in the NAc of female and male rats that
received intra-NAc infusions of the viral vector, AAV-CRF. In the contralateral hemisphere, rats
received intra-NAc infusions of the control vector, AAV-GFP. Three weeks later, dialysate levels
of dopamine, glutamate, and GABA were assessed in the NAc of both hemispheres during baseline
and then following nicotine administration. It was hypothesized that CRF overexpression would
enhance dopamine release in the NAc to a greater extent in females that experience stronger
nicotine reward than males based on our prior work published in Uribe et al., (2020). The rationale
for our hypotheses is based on previous work showing acute activation of CRF increases dopamine
levels in the NAc (Chen et al., 2012) and intra-NAc infusions of CRF produce place preference in
naïve rats (Lemos et al., 2012). Another report found overexpression of CRF in the NAc selectively
enhanced the reinforcing effects of nicotine in female versus male rats (Uribe et al., 2020). We
also anticipated that the increase in dopamine levels would be modulated via greater excitatory
glutamate and reduced GABA inhibition in the NAc.
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Chapter 2: Materials & Methods
2.1 Adeno-associated virus
Advancements in the fields of neuroscience and virology have resulted in the application of
viral vectors that can serve as tools to alter the expression of biological material in neurons. Viral
vectors incorporate into the nucleus of the cell to alter expression levels of the gene of interest,
such as CRF. In this way, viral vectors allow researchers to evaluate the functional role of an array
of different genes in discrete brain regions in specific neurons that are infected (Aschauer et al.,
2013). Different serotypes of the AAV vector determine the rate and efficiency at which the AAV
infects the cell. We chose the AAV2/5 hybrid serotype because it transduces neurons effectively
(Wu et al., 2006) and reliably maintains gene expression for up to 8 weeks (Qi et al., 2014).
Two viral vectors were obtained from a commercial vendor (Vector BioLabs, Philadelphia,
PA, USA) and were made to a specific titer concentration in a previously published paper (Qi et
al., 2014). The first viral vector is the AAV2/5-CRF. The viral vector has the rat CRF cDNA
(GenBank accession number NM_031019) packaged into it. The second viral vector is the
AAV2/5-GFP and will be the control vector. The viral vector has the humanized green fluorescent
protein (GFP) cDNA packaged into it. GFP is an inert protein that has no biological effect and
exhibits green fluorescence when exposed to 488 nm to 510 nm spectrum range. An advantage of
a commercial vendor is the viral vectors can be obtained in a timely manner, have been shown to
have a high transduction efficiency in neurons (>90%), and maintains reliable expression of CRF
and GFP for 3-8 weeks.
The AAV follows a preprogrammed infection cycle (Synder and Moullier, 2011; Wu et al.,
2006). The AAV enters into the nucleus of the cell, whereby it goes into the leading strand of the
DNA and replicates using the cellular polymerase to replicate (Goncalves 2005). Replication of
the virus leads to increases of mRNA of the gene of interest, leading to translation and increases
9

of the protein (Georgiadis et al., 2016). An important caveat is that while the AAV increases
mRNA expression, it does not always lead to increases of protein expression (Anderson et al.,,
1997; Washburn et al., 2003). This may be due to several reasons such as degradation or
differences in translation per mRNA (Li et al., 2017) . However, a prior study from our laboratory
has shown inta-NAc infusion of the AAV2/5-GFP does result in increases of protein expression
of GFP as shown by an increase in florescence (Uribe et al., 2020).
2.2 Neurochemical methods
In vivo microdialysis procedures estimate changes in levels of neurotransmitters in the
extracellular space of a discrete brain region. Dialysis studies provide valuable insights into how
the neurochemical environment changes in response to drug administration (Chefer et al., 2009).
In this procedure, a dialysis probe with a semipermeable membrane is inserted into the brain region
of interest. The membrane excludes proteins and molecules above a molecular weight that is
dependent on the pore size of the membrane, allowing for the collection of the neurotransmitters
(Hamberger et al., 1983; Kendrick 1989). A buffer made of artificial cerebrospinal fluid (aCSF) is
infused through the inlet of the probe at a constant rate via a syringe pump. The infusion of aCSF
perfusate creates a concentration gradient across the microdialysis membrane allowing for
neurotransmitters to diffuse into the membrane. The dialysate is then collected in a vial from the
outlet of the probe and is stored until it is analyzed using a variety of analytical methods.
Different methods have been used to measure neurotransmitter content in dialysate samples,
including high performance liquid chromatography (HPLC) electrochemical detection, HPLCfluorescence detection, capillary electrophoresis-laser induced fluorescence, and immunoassays
(Zapata et al., 2009). A limitation of these methods is that they only measure one neurotransmitter
at a time, lack sensitivity for detecting small changes in multiple neurotransmitter levels, and
require specific conditions to be run that may interfere with the detection of certain electroactive
10

compounds. This can be limiting when trying to study dynamic changes and relationships among
different neurotransmitter systems in brain regions where the content of these analytes is low.
Thus, the present work employed liquid chromatography-mass spectrometry (LC/MS) coupled
analysis. The rationale for using LC/MS is its capability for measuring many compounds in a
complex sample due to its high level of sensitivity and resolution. Although not utilized in our
protocol, additional rationale for using LC/MS includes the additional separation step where salts
are removed, reducing the complexity of the sample and allowing to optimize conditions for the
desired neurotransmitters (Annesley 2003; Zheng et al., 2012). Different compounds will be
retained and released in the column and LC/MS coupled analysis also gives us the capability to
detect neurotransmitters at a greater sensitivity when compared to traditional methods (Uutela et
al., 2009).
2.3 Subjects
Adult female and male Wistar rats were obtained from an out-bred stock of rats (Envigo
Inc; RRID:RGD_13508588) and were maintained on a reverse 12-hr light/dark cycle (lights on at
6:00 PM and off at 6:00 AM) in a humidity- and temperature- controlled vivarium (22◦C). The rats
were pair-housed in standard ventilated hanging cages (41.5 cm long × 17 cm wide × 21 cm high).
The rats had ad libitum access to food and water throughout the study. Following intracranial
infusions, rats were moved to a separate humidity- and temperature- controlled room. They were
singly-housed and maintained on a regular 12-hr light/dark cycle (lights on at 6:00 AM and off at
6:00 PM). All procedures were approved by The University of Texas at El Paso Institutional
Animal Care and Use Committee, and the 2011 Guide for Care and Use of Laboratory Animals
(Institute of Laboratory, Animals Resources on Life Sciences, the National Research Council, and
the National Academy of Sciences; reference number: A-201307-01). Although our hypotheses
were not pre-registered or our sample size predetermined by a priori power analysis, the
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experimental procedures, sample size, and statistical approach used in this report were based on
prior published works (Carcoba et al., 2018; O’Dell et al., 2013).
2.4 Procedural summary
The procedures are summarized in Figure 1. Rats were anesthetized with an isoflurane/oxygen
vapor mixture (1-3%) and were placed into a stereotaxic apparatus. The head of the rat was sliced
and the skin was held open with hemostats. Once the head was placed into a flat skull position,
two holes were drilled using the following coordinates from bregma for the NAc (AP = +1.7, ML
= ±1.4 mm) using the rat brain atlas of Paxinos and Watson rat atlas (2004). The coordinates from
bregma to infuse the viral vectors were: AP = +1.7, ML = ±1.4, DV = -9.1 mm (from skull). All
rats received an infusion of the viral vector, AAV2/5-CRF, in the NAc of one hemisphere. The
injections were made using a syringe pump (Harvard 22, Harvard Apparatus, Holliston, MA, USA)
using an injection volume of 0.5 µls over a 3-min period. The injectors were left in place an
additional 5-min to allow proper diffusion from the injector tip. In the contralateral NAc, rats
received an infusion of the control virus, AAV2/5-GFP, to overexpress GFP. The hemisphere with
the GFP viral vector will be the “control” hemisphere. Rats remained undisturbed for three weeks
after intracranial infusions to allow for viral incubation and replication. Previous research has
shown that AAV replication of our virus reaches maximal overexpression 2 weeks later, and
remains constant for 8 weeks in brain tissue (Qi et al., 2014). Simple randomization for viral
infusion occurred prior to the start of the experiment via a number labeling system for each rat.
The viral infusions were also counter-balanced across brain hemispheres. The experimenters were
unaware to the subjects’ viral condition during dialysis testing and the sample preparation for the
analysis of neurotransmitter content.
Dual microdialysis probes with an active membrane length of 2 mm were aimed into both
NAc (model CMA11, Holliston, MA) using the coordinates as referenced above. The probes were
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perfused for at least 1 hr prior to probe placements at a rate of 1.0 μL/min with artificial
cerebrospinal fluid (aCSF) composed of 145 mM NaCl, 2.8 mM KCl, 1.2 mM CaCl2, 1.2 mM
MgCl2, 5.4 mM d-glucose, and 0.25 mM ascorbic acid and adjusted to a pH of 7.2–7.4. This
allowed us to examine changes in neurotransmitter release following overexpression of CRF in
one hemisphere and overexpression of GFP in the contralateral “control” hemisphere.
2.5 Dialysis testing
Following surgery, the rats were transferred to a PlexiglasⓇ cage (24 cm long × 24 cm wide
× 31 cm high) with food and water available throughout dialysis testing. Rats were left overnight
to recover and the probes were flushed with aCSF at a rate of 0.1 µl/min. The following day, one
hr before collection, the flow rate was adjusted to 0.6 μL/min for both probes prior to dialysate
collection.
Our dialysis regimen is shown in Figure 2. It consisted of 20-min sampling periods during
a baseline period and systemic administration of two doses of nicotine (0.3 and 0.6 mg/kg/base,
subcutaneous). Nicotine hydrogen ditartrate (NIDA, Research Triangle, Bethesda, MA, USA) was
dissolved in 0.9% sterile saline and adjusted to a pH level of approximately 7.4. All nicotine
solutions were prepared according to the rats’ body weight on the day of dialysis testing. These
nicotine doses were chosen based on our previous work sex differences in nicotine intake in this
dose range (Uribe et al., 2020). Dialysate was collected for three 20-min sampling periods (60
mins) for a baseline reading. Baseline levels were analyzed to give a basal and control level of
neurotransmitters before the treatment regimen. Following baseline, the first dose of nicotine was
injected and dialysate was collected for five 20-min sampling periods (100 mins) prior to the next
injection of nicotine. The dialysate samples were immediately frozen on dry ice and then stored at
−80 °C until assayed. At the end of dialysis testing, the rats were sacrificed using CO2 inhalation
and then decapitated to ensure euthanasia. The probes were then extracted and the brains were
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removed, frozen, and sliced in 20 μm coronal sections for verification of probe placement. Probe
placement was verified using gross observation of the probe track within the NAc shell using the
Paxinos and Watson rat atlas (2004).
2.6 Mass spectroscopy analysis
Following dialysate collection, quantification of neurotransmitters was performed using an
approach involving LC-MS analysis. The samples were analyzed using mass spectrometry analysis
of dopamine, glutamate, and GABA in each NAc. The neurochemical analyses were performed
using a Thermo Scientific UltiMate™ 3000 Standard Quaternary System with a Waters BEH C18
column (1 mm × 100 mm, 1.7 μm, 130 Å pore size) for separation. The autosampler was coupled
to a TSQ Endura triple quadrupole MS. Our mass spectrometry methods incorporated calibration
curves using standards ranging from 5, 50, 100, 500 and 1000 nM for GABA and glutamate, and
0.5, 5, 10, 50 and 100 nM for dopamine. The internal standard and sample derivatization
procedures followed the methods described in Buczynski et al (2016) and Song et al (2012).
Briefly, the composition of mobile phase A was 10 mM ammonium formate (0.15% (v/v) formic
acid in water). Mobile phase B was 100% acetonitrile. The mobile phase gradient for the
neurotransmitters lasted 10 minutes long and was: initial, 0% B; 0.1 min, 15% B; 2 min, 20% B;
2.3 min, 25% B; 2.31 min, 50% B; 5.31 min, 50% B; 5.57 min, 65 % B; 6.57 min, 65%B; 6.58
min, 0% B; 8.0 min, 0% B. Two blanks were run in-between to wash out any residue from the
previous sample to ensure there is no carryover or contamination. The peaks were visually
inspected to detect artifacts. Peak areas were obtained and analyzed for each neurotransmitter with
their respective internal standard. Standard curves were used to calculate the concentration of all
relevant neurotransmitters in each sample.
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2.7 Statistics
Our initial approach to the data analysis involved an overall ANCOVA analysis that
included all of our neurotransmitter measures. Since significant overall effects were not observed
in this larger analysis, we proceeded with traditional ANOVA approaches with separate analyses
of each neurotransmitter. Thus, separate mixed ANOVA analyses were used to compare group
differences in baseline and following nicotine administration changes across time. To determine if
the presence of the control virus caused changes in the release of neurotransmitters in the NAc of
female and male rats, baseline levels of dopamine, GABA, and glutamate in the control
hemispheres were assessed. The analysis compared baseline dialysate levels using two-way mixed
ANOVAs with sex (female or male) as a between subject factor and time (20-min sampling
periods) as a within subject factor. In order to provide a comparison of sex differences that
accounted for potential differences in baseline and following nicotine administration levels
produced by infusion of the viral vector, the data were converted to percent change from respective
control levels [(CRF dialysate value/average control value) × 100]. The first level of analysis
compared baseline levels using three-way mixed ANOVAs with virus (CRF or GFP) and sex
(female or male) as between subject factors and time (20-min sampling periods) as a within subject
factor. The second level of analysis compared dialysate levels following nicotine administration
using three-way mixed ANOVAs with virus (CRF or GFP) and sex (female or male) as between
subject factors and time (20-min sampling periods) as a within subject factor. For the repeated
measures analyses with more than three levels, a test for the assumption of normality was
employed using the Mauchly-Sphericity test. In cases where violations of normality occurred, a
Huynh–Feldt correction factor modified the degrees of freedom, which resulted in an adjusted Fratio. Where main or interaction effects were observed, planned comparisons were conducted
using the Bonferroni correction factor, because it would yield a more conservative p-value for
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multiple comparisons (p<0.05). All statistical analyses were performed on SPSS version 26, and
all of the graphs were generated using GraphPad Prism version 8.
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Chapter 3: Results
3.1 Analysis of sex differences in GFP control rats
In order to best illustrate sex differences, we present the data as % change from respective GFP
controls during baseline (Figure 3) and following nicotine administration (Figure 4). We first
needed to examine whether females and males begin at an equivalent starting point. Table 1
depicts the baseline levels in the control NAc hemisphere in female and male rats. In the control
hemisphere, the analysis of dopamine revealed that there was no interaction between time and sex
[F (2, 20) = 0.70, p = 0.51]. Also, there was no main effect of sex [F (1,10) = 0.11, p = 0.74]. The
analysis of GABA revealed that there was no interaction between time and sex [F (1.57, 15.69) =
0.02, p = 0.96]. Also, there was no main effect of sex [F (1, 10) = 0.25, p = 0.88]. The analysis of
glutamate revealed that there was no interaction between sex and time [F (2, 20) = 1.69, p = 0.21].
Also, there was no main effect of sex [F (1, 10) = 0.68, p = 0.43].

3.2 Aim 1: Baseline sex differences
Figure 3 depicts percent (%) change baseline values in dopamine, glutamate, and GABA in
CRF overexpressing female and male rats. The analysis of dopamine revealed that there was no
interaction between time, sex, and virus [F (2, 44) = 0.78, p = 0.47]. Also, there was no main effect
of sex [F (1, 22) = 0.03, p = 0.87] or virus [F (1, 22) = 3.87, p = 0.062]. The analysis of glutamate
revealed that there was no interaction between time, sex, and virus [F (2, 44) = 1.27, p = 0.29].
However, there was a interaction between sex and virus [F (1, 22) = 7.01, p = 0.02], with females
showing a decrease in glutamate levels at all sampling points and males showing greater glutamate
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levels at the first sample point when compared to their respective controls (*p<0.05). With regard
to sex differences, CRF overexpressing males displayed greater glutamate release than CRF
overexpressing females at all sampling periods. The analysis of GABA revealed that there was no
interaction between time, sex, and virus [F (2, 44) = 0.19, p = 0.82]. Also, there was no main effect
of sex [F (1, 22) = 0.27, p = 0.61] or virus [F (1, 22) = 2.29, p = 0.15].
3.3 Aim 2: Sex differences following nicotine administration
Figure 4 depicts percent (%) change in dopamine, glutamate, and GABA levels following
administration of two nicotine doses (0.3 and 0.6 mg/kg/base) in CRF overexpressing female and
male rats. The analysis of dopamine revealed that there was no interaction between time, sex, and
virus [F (12, 264) = 1.05, p = 0.41]. Also, there was no main effect of sex [F (1, 22) = 1.25, p =
0.28] or virus [F (1, 22) = 2.01, p = 0.17]. The analysis of glutamate revealed that there was no
interaction between time, sex, and virus [F (12, 264) = 0.99, p = 0.46]. However, there was a twoway interaction between sex and virus [F (1, 22) = 0.4.01, p = 0.05], with females showing a
decrease in glutamate release at the 4th and 6th sampling period and male showing greater glutamate
release at the 9th sampling period when compared to their respective controls. With regards to sex
differences, CRF overexpressing males show greater glutamate during the 9th, 10th, and 12th
sampling period when compared to CRF overexpressing females. The analysis of GABA revealed
that there was no interaction between time, sex, and virus [F (12, 264) = 0.91, p = 0.54]. Also,
there was no main effect of sex [F (1, 22) = 0.102, p = 0.75] or virus [F (1, 22) = 0.10, p = 0.76].
3.4 Probe verification
Our estimates of the probe placements were superimposed on digital images derived from the
Paxinos and Watson atlas (2004). Figure 5 illustrates our probe placements in the NAc of CRF
overexpressing (red probe) and GFP controls (green probe). Each line reflects our estimate of the
placement of the membrane sampling portion of the probe collected during sectioning. The left
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panel reflects placements in female rats and the right panel reflects placements in the male rats.
The diameter of the probe membrane was 0.24 mm wide, such that the estimated drawings of the
probe span a range of sections wider than what is noted on a single plate in the diagram. The
schematic illustrates that our probe placements were contained in the NAc shell. Two animals (2
females) were omitted from the study because of improperly placed microdialysis probes missing
the NAc shell. At the end, females (n = 8) and males (n = 4) were included in the final analyses.
We recognize that the number of male subjects is low, and this might have contributed to a lack of
statistical power and significant results in the analyses of the selected neurotransmitters.
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Chapter 4: Discussion
4.1 Summary
The main finding of this dissertation is that CRF differentially modulates the neurochemical
effects of nicotine in the NAc of female and male rats. Overexpression of GFP did not alter
dopamine, GABA, or glutamate in female versus male rats. During baseline, CRF overexpression
altered glutamate release in sex-dependent manner, with male rats displaying an increase in
glutamate and female rats displaying a decrease in glutamate levels. Similarly, following nicotine
administration, CRF overexpression increased glutamate levels in males and decreased glutamate
levels in females.
4.2 Aim 1: Sex differences during baseline
We first focused on baseline differences to assess the effects of CRF overexpression on tonic
release of key neurotransmitters in the NAc. Our major finding was that during baseline, overexpression of CRF in the NAc significantly increased glutamate release in male rats. We suggest
that CRF overexpression created a shift in the NAc towards a greater excitatory neurochemical
environment. Consistent with this, prior work in male mice revealed that optogenetic activation of
glutamatergic inputs into the NAc produced conditioned place preference (Britt et al., 2012). This
suggests that enhanced glutamatergic input to the NAc elicits rewarding effects in male rats.
Interestingly, the present study revealed that CRF overexpression in the NAc decreased baseline
glutamate release in females relative to their GFP control group. Although the effects were not
significant, both CRF overexpressing female and male rats displayed a trend for an increase in
dopamine release when compared to control rats. This pattern of results came as a surprise as
previous studies have shown CRF micro-infusion into the NAc increases dopamine levels (Chen
et al., 2012) and produces place preference in naïve rats (Lemos et al., 2012). Furthermore,
following stress induction, dopamine levels in the NAc shell are elevated (Kalivas et al., 1995; Wu
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et al., 1999). The lack of significance may be related to the low sample size in the study. Although
not statistically significant, both CRF female and male rats displayed a trend for a decrease in
GABA levels (Figure 3C). There is evidence that CRF+ neurons colocalize with the GABAergic
marker, GAD 65 and GAD 67, suggesting that CRF modulates GABA release (Chen et al., 2004;
Yan et al., 1998). Together, these data suggest that CRF overexpression altered the tonic release
of amino acids in the NAc. This effect was observed in a sex-dependent manner, with male rats
displaying greater excitatory glutamate release and females displaying reduced excitatory input
to the NAc. Thus, CRF overexpression in the NAc altered the neurochemical environment towards
greater excitatory potential in males prior to nicotine administration, as described below.
4.3 Aim 2: Sex differences following nicotine administration
Figure 6 below summarizes our results regarding the effects of CRF overexpression on key
neurotransmitters in the NAc following phasic changes in synaptic release following nicotine
administration. The results revealed that following nicotine administration, CRF overexpression
increased glutamate in males, whereas glutamate levels were decreased in females. The relatively
higher excitatory glutamate input in males appeared to have contributed to the trend towards sex
differences in nicotine-induced dopamine release in the NAc. This suggestion is based on the males
displaying higher dopamine levels following nicotine administration than females. We speculate
that CRF overexpression enhances glutamatergic transmission in males in a manner that “primes”
the NAc for stronger neurochemical effects of nicotine as compared to females. In male rats, prior
work has shown that antagonists for both ionotropic and metabotropic glutamate receptors block
nicotine-induced dopamine release in the NAc (Kosowski et al., 2004). In striatal cells, previous
work has shown that amino acid systems modulate dopamine release (Chiodo et al., 1986; Kitai et
al., 1976). Indeed, Hjelmstad (2004) demonstrated that chronic exposure of striatal cells to
dopamine decreased GABAergic inhibition, and this resulted in a greater excitation of these
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neurons. Together, these data suggest that CRF overexpression in males increases excitatory
transmission in the NAc in a manner that “primes” this brain region for greater nicotine-induced
dopamine release that is larger relative to females. Below we provide a hypothesized mechanism
for the manner in which viral overexpression of CRF may have produced sex-dependent effects in
our neurochemical measures. The ANCOVA analysis revealed there were no significant CRFinduced changes in dopamine, GABA, or glutamate levels in the study. This may due to the
relatively low sample size of female and male rats in the study. We acknowledge the low sample
size in males may have contributed to a lack of statistical power in our results as explained further
below.
4.4 Hypothesized mechanisms
Our proposed mechanistic hypothesis is that sex differences in the behavioral and
neurochemical effects of nicotine are modulated via inhibitory (GABA) and excitatory (glutamate)
amino acids that regulate dopamine release in the NAc (see Figure 6). Our proposed circuitry
focuses on the shell of the NAc based on the distribution of CRF receptors in this region and the
anatomical continuity of the shell with the extended amygdala, which is believed to modulate drug
addiction (Balfour, 2009; Koob, 2010). We offer that CRF overexpression alters nAChR and CRF1
receptors that modulate sex differences in amino acid control of dopamine release in the NAc.
First, prior work has shown that females display higher plasma CRF levels in response to a stressor
and increased activation of CRF receptors, and a weaker negative feedback inhibition of the HPA
axis (Bangasser et al., 2010; Kokras et al., 2019). My previous work also revealed that
overexpression of CRF produced a larger downregulation of CRF1 receptors in the NAc of male
versus female rats (Uribe et al., 2020). We propose that males display a larger down regulation of
CRF1 receptors on glutamatergic terminals in the NAc. It is expected that this effect might result
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in an enhancement of excitatory glutamate release, which would then enhance dopamine release
produced by nicotine administration in the NAc of male versus female rats.
Our hypotheses regarding CRF1 receptors is in line with prior work showing that male rats
display greater internalization of CRF1 receptors than females. Specifically, male rats display
greater expression of the CRF1 internalizing protein, β-arrestin2, as compared to females
(Bangasser et al., 2010; Valentino et al., 2013). Indeed, our prior work revealed that CRF
overexpression in the NAc produced a greater increase in β-arrestin2 levels in males versus
females (Uribe et al., 2020). Thus, we posit that males would display a large downregulation of
CRF1 receptors which would result in a reduction in the ability of CRF to reduce glutamatergic
input to the NAc in males versus females. In females, our hypothesis that CRF receptors produce
greater effects than in males is consistent with prior work. For example, Weathington et al (2014)
found that female rats display a greater increase in CRF binding to CRF1 receptors than males,
suggesting that ovarian hormones enhance CRF1 receptor-mediated effects. For example, the
highest levels of CRF are observed during proestrus when estradiol levels are highest (Bohler et
al., 1990). Direct activation of estrogen receptor-β (ERβ) increases CRF mRNA expression in vitro
(Zhu and Zhou, 2008). Also, the E2 gene sequence promotes CRF gene transcription
(Vamvakopoulos and Chrousos, 1993). Together, these data suggest that CRF1 receptors may
modulate sex differences in the neurochemical effects of nicotine via changes in glutamate release
in the NAc. It is noteworthy that male rats only displayed an increase in glutamate following
administration of the high dose of nicotine. This may be related to activation of α7-type nAChRs
that are located on glutamatergic terminals that project to the NAc from the prefrontal cortex
(Marchi et al., 2002; Pirttimaki et al., 2013). Indeed, previous work has shown α7 nAChRs are
preferentially activated under conditions involving higher nicotine concentrations (Lester and
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Dani, 1995; Wooltorton et al., 2003). Thus, the possibility that greater expression of a7 receptors
that may also enhance glutamate release in the NAc.
4.5 Limitations and future directions
A major limitation of this dissertation relates to the relatively lower sample size in male versus
female rats. Specifically, the sample size for our neurochemical measures was larger in females (n
= 8) versus males (n = 4). We recognize that our low sample size in males may have contributed
to a lack of statistical power in our results. Importantly, we did find that overexpression of CRF
produced significant effects in glutamate transmission in the NAc of males, and our analyses for
dopamine and GABA revealed strong trends that will be addressed with more animals once the
current pandemic-related restrictions are lifted. We have collected additional female (n =1) and
male (n = 2) rats that will be analyzed prior to the publication of my dissertation work.
Another limitation of this dissertation work is that we did not track the estrous cycle of the
female rats. This information would have been informative based on recent work showing that
ovarian hormones alter the behavioral effects of nicotine. Specifically, estradiol enhances the
rewarding effect of nicotine, whereas progesterone reduces the behavioral effects of nicotine
withdrawal (Flores et al., 2016; 2019). Differences in dopamine levels has been partly attributed
to the estrous cycle and relatively higher levels of estradiol as greater DA release has been observed
in females in proestrus (Xiao et al., 1994). In addition, OVX female rats display a reduction in
dopamine release in the striatum and, following estradiol supplementation, is restored to intact
female levels (Becker, 1990). Interestingly, castration of males does not reduce DA concentration
when compared to intact males (Xiao et al., 1994; Castner et al., 1993). This study is the first step
towards evaluating CRF modulation of sex differences in the neurochemical effects of nicotine in
the NAc. Future studies are needed to more closely examine the manner in which fluctuations in
ovarian hormones influence the contribution of stress systems in the neurochemical effects of
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nicotine. For example, one might consider examining how overexpression of CRF alters nicotineinduced neurochemical effects in OVX female rats supplemented with estradiol and/or
progesterone.
A final limitation is that we only focused on neurochemical effects of nicotine in the NAc, and
one might expect that this brain region does not modulate sex differences in isolation. Indeed,
ongoing work in our laboratory is showing that sex differences in nicotine withdrawal are mediated
by amino acids in the interpeduncular nucleus (IPN). The present work is a first step in a long line
of work examining the underlying neural mechanisms that modulate sex differences produced by
nicotine and withdrawal from this drug. There may also be other neurotransmitter systems, such
as acetylcholine (ACh) that modulate sex differences in the neurochemical effects of nicotine in
the NAc. This suggestion is based on the work of Lemos et al (2019) who found that CRF1 receptor
activation increases the firing of cholinergic interneurons in the NAc. The present work laid the
groundwork for future studies aimed at uncovering the underlying mechanisms that promote sex
differences produced by nicotine.
4.6 Conclusions and significance
The current study found that CRF systems in the NAc modulate the neurochemical effects of
nicotine, with males displaying greater excitatory regulation of the NAc, a key structure that
modulates the motivational properties of drug abuse. In contrast, CRF overexpression seemed to
dampen the neurochemical effects of nicotine on dopamine transmission in the NAc of females.
Our prior work revealed that overexpression of CRF in the NAc increased the reinforcing effects
of nicotine to a larger extent in female versus male rats (Uribe et al., 2020). Thus, we expected that
overexpression of CRF in the NAc of females would result in greater (not reduced) nicotineinduced dopamine release in the NAc. It is possible; however, that the strong reinforcing effects
of nicotine in females is not modulated via dopamine release in the NAc. It is also possible that
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female rats may have to self-administer higher amounts of nicotine to compensate for reduced
dopamine release in the NAc. Indeed, parallel work in our laboratory has shown that diabetic rats
display greater nicotine self-administration, but reduced nicotine-induced dopamine release in the
NAc (O’Dell and Nazarian, 2015). Thus, enhanced drug intake may be related to an
overcompensation of reduced dopamine transmission, a hypothesis that has been posited to explain
compulsive overeating behavior (Yoshida et al., 1992). Future studies are needed to better
understand how amino acid systems modulate greater vulnerability to nicotine use in vulnerable
populations, such as females that are more susceptible to nicotine use than males in a clinical
setting. This work is important toward the development of more effective cessation strategies that
target stress systems that may help reduce health disparities produced by nicotine in women.
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Figure 1: The schematic illustrates intra-NAc infusion of the AAV2/5-CRF in one hemisphere
and infusion of the control virus, AAV2/5-GFP, in the contralateral hemisphere in female and male
rats. Three weeks later, two dialysis probes with semi-permeable membrane into the NAc of both
hemispheres.
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Figure 2: The schematic illustrates the dialysis regimen and timeline during collection day.
Dialysate samples were collected in 20-minute sample periods for baseline and following
injections of two doses of nicotine.
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Figure 3: NAc levels of dopamine, glutamate, and GABA during baseline. The top panel (A)
reflects dopamine, the bottom left panel (B) reflects glutamate, and the bottom right panel (C)
reflects GABA in CRF overexpressing females (open circles) and males (open circles). Data are
expressed as percent (%) change (CRF value/control value * 100) with values above and below
the dotted line representing an increase or decrease in dialysate levels, respectively. The asterisk
(*) denotes a significant difference from respective GFP control group and the daggers (†) denote
a significant difference from CRF overexpressing female rats (p ≤ 0.05).
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Figure 4: NAc levels of dopamine, glutamate, and GABA during baseline and following nicotine
administration. The top panel (A) reflects dopamine, the bottom left panel (B) reflects glutamate,
and the bottom right panel (C) reflects GABA in CRF overexpressing females (open circles) and
males (open circles). Data are expressed as percent (%) change (CRF value/control value * 100)
with values above and below the dotted line representing an increase or decrease in dialysate levels,
respectively. The asterisk (*) denotes a significant difference from respective control group and
the daggers (†) denote a significant difference from CRF overexpressing female rats (p ≤ 0.05).
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Figure 5: The schematic illustrates microdialysis probe placements in the NAc of both
hemispheres in female and male rats. Probe placements were localized to the NAc shell in both
hemispheres.
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Figure 6: The image summarizes the neurochemical effects of CRF overexpression in the
mesocorticolimbic pathway of female and male rats. CRF overexpression increased glutamate and
dopamine release in male rats. In contrast, CRF decreases glutamate and dopamine release in
females. It is hypothesized that the latter effect is mediated via greater expression of CRF1 receptor
on excitatory terminals in female rats. Importantly, reduced expression of CRF1 receptor and
activation of α7-type receptors on PFC terminals increase glutamatergic release, enhancing
nicotine-induced dopamine transmission in male rats. (Abbreviations: GLU, glutamate; GABA, γamino butyric acid; DA, dopamine; PFC, prefrontal cortex; VTA, ventral tegmental area; NAc,
nucleus accumbens; CRF, corticotrophin-releasing factor; CRF1, corticotrophin-releasing factor 1
receptor; nAChR, nicotinic acetylcholine receptor).
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